Found: 26
Select item for more details and to access through your institution.
Cutaneous annular lesions as the first sign of transformation of follicular lymphoma into diffuse large B-cell lymphoma.
- Published in:
- 2015
- By:
- Publication type:
- Case Study
Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01065-z
- By:
- Publication type:
- Article
Lenalidomide in combination with R‐ESHAP in patients with relapsed or refractory diffuse large B‐cell lymphoma: A phase 2 study from GELTAMO.
- Published in:
- British Journal of Haematology, 2023, v. 203, n. 2, p. 202, doi. 10.1111/bjh.18989
- By:
- Publication type:
- Article
Peripheral T‐cell lymphoma with a T follicular‐helper phenotype: A different entity? Results of the Spanish Real‐T study.
- Published in:
- British Journal of Haematology, 2023, v. 203, n. 2, p. 182, doi. 10.1111/bjh.18941
- By:
- Publication type:
- Article
Psicoterapia grupal en duelo. Experiencia de la psicología clínica en Atención primaria.
- Published in:
- Revista de la Asociación Española de Neuropsiquiatría, 2015, v. 35, n. 126, p. 383, doi. 10.4321/S0211-57352015000200011
- By:
- Publication type:
- Article
Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 1, p. 70, doi. 10.3390/jcm13010070
- By:
- Publication type:
- Article
Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain.
- Published in:
- Cancers, 2024, v. 16, n. 13, p. 2301, doi. 10.3390/cancers16132301
- By:
- Publication type:
- Article
Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups.
- Published in:
- Cancers, 2022, v. 14, n. 22, p. 5670, doi. 10.3390/cancers14225670
- By:
- Publication type:
- Article
Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial.
- Published in:
- Cancers, 2021, v. 13, n. 18, p. 4622, doi. 10.3390/cancers13184622
- By:
- Publication type:
- Article
Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2023.1188818
- By:
- Publication type:
- Article
Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
- Published in:
- Frontiers in Immunology, 2023, p. 01, doi. 10.3389/fimmu.2023.1188818
- By:
- Publication type:
- Article
Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1188818
- By:
- Publication type:
- Article
ABCL-181: Updated Results of a Phase 2 Study from GELTAMO Investigating the Combination of Ibrutinib with R-GEMOX in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S381, doi. 10.1016/S2152-2650(21)01868-1
- By:
- Publication type:
- Article
Poster: ABCL-181: Updated Results of a Phase 2 Study from GELTAMO Investigating the Combination of Ibrutinib with R-GEMOX in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S239, doi. 10.1016/S2152-2650(21)01500-7
- By:
- Publication type:
- Article
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice.
- Published in:
- International Journal of Hematology, 2022, v. 116, n. 3, p. 381, doi. 10.1007/s12185-022-03367-z
- By:
- Publication type:
- Article
FIVE‐YEAR UPDATE OF THE FIRST‐LINE IMCL‐2015 GELTAMO STUDY. PROLONGED MOLECULAR AND CLINICAL RESPONSES WERE OBSERVED AFTER MRD‐DRIVEN IBRUTINIB DISCONTINUATION.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 148, doi. 10.1002/hon.3163_98
- By:
- Publication type:
- Article
Novel therapies for the treatment of relapsed‐refractory aggressive B‐cell lymphoma increase survival. Analysis from the RELINF registry of the GELTAMO group.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 434, doi. 10.1002/hon.3164_320
- By:
- Publication type:
- Article
A low lymphocyte‐to‐monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 290, doi. 10.1002/hon.3164_200
- By:
- Publication type:
- Article
OUTCOMES OF PATIENTS WITH LYMPHOMA AND COVID‐19: AN OBSERVATIONAL COHORT STUDY FROM GELTAMO SPANISH GROUP.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.200_2880
- By:
- Publication type:
- Article
UPDATED RESULTS OF A PHASE 2 STUDY FROM GELTAMO INVESTIGATING THE COMBINATION OF IBRUTINIB WITH R‐GEMOX IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.94_2880
- By:
- Publication type:
- Article
EFFICACY AND SAFETY OF IBRUTINIB IN COMBINATION WITH RITUXIMAB AS FRONTLINE TREATMENT FOR INDOLENT CLINICAL FORMS OF MANTLE CELL LYMPHOMA. RESULTS OF THE GELTAMO IMCL‐2015 STUDY.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.60_2879
- By:
- Publication type:
- Article
CHARACTERIZATION OF THE ONCOGENIC PHENOTYPE IN EXTRANODAL NATURAL KILLER/T‐CELL LYMPHOMA, NASAL TYPE THROUGH GENE EXPRESSION PROFILE. SPANISH LYMPHOMA GROUP GELTAMO.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.139_2880
- By:
- Publication type:
- Article
LENALIDOMIDE PLUS R‐GDP (R2‐GDP) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA. PRELIMINARY RESULTS OF THE R2‐GDP‐GOTEL TRIAL.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 258, doi. 10.1002/hon.67_2630
- By:
- Publication type:
- Article
LENALIDOMIDE PLUS R‐GDP (R2‐GDP) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA. PRELIMINARY RESULTS OF THE R2‐GDP‐GOTEL TRIAL.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 258, doi. 10.1002/hon.67_2630
- By:
- Publication type:
- Article
A novel NKp80-based strategy for universal identification of normal, reactive and tumor/clonal natural killer-cells in blood.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1423689
- By:
- Publication type:
- Article
CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDPGOTEL trial in recurrent/refractory diffuse large B cell lymphoma.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1293931
- By:
- Publication type:
- Article